These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 25714044

  • 21. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, Group T, Lin J, Luxembourg A, Walia A, Tu Y.
    Hum Vaccin Immunother; 2022 Nov 30; 18(6):2105067. PubMed ID: 35997582
    [Abstract] [Full Text] [Related]

  • 22. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.
    Lancet; 2017 Nov 11; 390(10108):2143-2159. PubMed ID: 28886907
    [Abstract] [Full Text] [Related]

  • 23. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C, Ramírez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, Lopez-Ruz M, Pasquau J.
    AIDS Res Ther; 2017 Jul 18; 14(1):34. PubMed ID: 28720147
    [Abstract] [Full Text] [Related]

  • 24. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
    Mugo NR, Eckert L, Magaret AS, Cheng A, Mwaniki L, Ngure K, Celum C, Baeten JM, Galloway DA, Wamalwa D, Wald A.
    Vaccine; 2018 Nov 12; 36(46):7025-7032. PubMed ID: 30297124
    [Abstract] [Full Text] [Related]

  • 25. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J.
    Hum Vaccin Immunother; 2015 Nov 12; 11(6):1313-22. PubMed ID: 25912208
    [Abstract] [Full Text] [Related]

  • 26. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.
    PLoS One; 2013 Nov 12; 8(5):e61825. PubMed ID: 23650505
    [Abstract] [Full Text] [Related]

  • 27. The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13 year-old girls: Is it influenced by age, menarche status or body mass index?
    Sauvageau C, Gilca V, Donken R, Fan SY, Ogilvie G, Dobson S.
    Vaccine; 2019 Nov 20; 37(49):7203-7206. PubMed ID: 31648910
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years.
    Hidalgo-Tenorio C, Pasquau J, Omar-Mohamed M, Sampedro A, López-Ruz MA, López Hidalgo J, Ramírez-Taboada J.
    Viruses; 2021 Jan 20; 13(2):. PubMed ID: 33498165
    [Abstract] [Full Text] [Related]

  • 29. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
    Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G, HPV-010 Study Group.
    Hum Vaccin; 2011 Dec 20; 7(12):1343-58. PubMed ID: 22048173
    [Abstract] [Full Text] [Related]

  • 30. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
    Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol RJ.
    Vaccine; 2017 May 09; 35(20):2642-2646. PubMed ID: 28404357
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M.
    Vaccine; 2014 Oct 29; 32(47):6303-11. PubMed ID: 25218297
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group.
    Hum Vaccin; 2009 Oct 29; 5(10):705-19. PubMed ID: 19684472
    [Abstract] [Full Text] [Related]

  • 33. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T, Liu Y, Li Y, Liao Y, Shou Q, Zheng M, Liao X, Li R.
    Vaccine; 2018 Mar 07; 36(11):1368-1374. PubMed ID: 29428178
    [Abstract] [Full Text] [Related]

  • 34. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J.
    Contemp Clin Trials; 2015 May 07; 42():18-25. PubMed ID: 25749310
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
    Watson-Jones D, Changalucha J, Whitworth H, Pinto L, Mutani P, Indangasi J, Kemp T, Hashim R, Kamala B, Wiggins R, Songoro T, Connor N, Mbwanji G, Pavon MA, Lowe B, Mmbando D, Kapiga S, Mayaud P, de SanJosé S, Dillner J, Hayes RJ, Lacey CJ, Baisley K.
    Lancet Glob Health; 2022 Oct 07; 10(10):e1473-e1484. PubMed ID: 36113531
    [Abstract] [Full Text] [Related]

  • 36. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
    Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, Sawata M, Tanaka Y.
    Vaccine; 2019 Mar 14; 37(12):1651-1658. PubMed ID: 30797638
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Huang Z, He J, Su J, Ou Z, Liu G, Fu R, Shou Q, Zheng M, Group T, Luxembourg A, Liao X, Zhang J.
    Vaccine; 2021 Jan 22; 39(4):760-766. PubMed ID: 33239228
    [Abstract] [Full Text] [Related]

  • 38. Post-approval Safety Monitoring of Quadrivalent and Bivalent Human Papillomavirus Vaccines Based on Real-world Data from the Korea Adverse Events Reporting System (KAERS).
    Kim M, Kim S, Shin JY.
    Clin Drug Investig; 2020 Aug 22; 40(8):727-735. PubMed ID: 32474825
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
    Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli UR, Jivarajani P, Verma Y, Zomawia E, Siddiqi M, Shastri SS, Jayant K, Malvi SG, Lucas E, Michel A, Butt J, Vijayamma JM, Sankaran S, Kannan TP, Varghese R, Divate U, Thomas S, Joshi G, Willhauck-Fleckenstein M, Waterboer T, Müller M, Sehr P, Hingmire S, Kriplani A, Mishra G, Pimple S, Jadhav R, Sauvaget C, Tommasino M, Pillai MR, Indian HPV Vaccine Study Group.
    Lancet Oncol; 2016 Jan 22; 17(1):67-77. PubMed ID: 26652797
    [Abstract] [Full Text] [Related]

  • 40. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P, Meijer CJLM, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M.
    Vaccine; 2016 Jul 29; 34(35):4205-4212. PubMed ID: 27354258
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.